SERPINB9 (SPB9) has been reported as a critical factor in the resistance to immunotherapy but its role in chemosensitivity remains unknown. Here this work reports that gemcitabine (GEM) treatment leads to upregulation of SPB9 in vitro/vivo, therefore engineer a nanocarrier co-delivering GEM and siSPB9 for preclinical pancreatic cancer treatment.
- Haozhe Huang
- Yiqing Mu
- Song Li
